US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app, which features missed meal dose detection. This innovation marks a significant step in the launch of Medtronic’s Smart MDI system, integrated with the Simplera continuous glucose monitor (CGM).
InPen App: A Pioneer in Real-Time Insulin Dose Adjustments
The InPen app becomes the first in the market to recommend corrections for missed or inaccurate insulin doses. It provides real-time, personalized insights for individuals on multiple daily injection (MDI) therapy, enhancing the precision and effectiveness of insulin management.
Integrating InPen with Simplera CGM for Enhanced Diabetes Management
Medtronic’s Smart MDI system combines the company’s InPen smart insulin pen with its newest Simplera CGM. The Simplera CGM is Medtronic’s first disposable, all-in-one CGM that is half the size of previous models, offering a more streamlined approach to diabetes health management. This integration is expected to simplify the lives of diabetes patients by providing a comprehensive and user-friendly monitoring and treatment solution.-Fineline Info & Tech
Leave a Reply